Rinatabart Sesutecan

DRUG5 trials

Sponsors

Genmab A/S

Conditions

Endometrial Cancer AdvancedGastrointestinal CancersLocally advanced or metastatic Non-Small Cell Lung CancerMetastaticOvarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)RecurrentRecurrent Platinum-Sensitive Ovarian Canceror Primary Unresectable Endometrial Cancer

Phase 2

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Non-Small Cell Lung Cancer

Not yet recruitingCTIS2025-522107-18-00

Genmab A/SLocally advanced or metastatic Non-Small Cell Lung Cancer

Target: 34Updated: 2026-04-15

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers

Not yet recruitingCTIS2025-524130-26-00

Genmab A/SGastrointestinal Cancers

Target: 53Updated: 2026-08-27

Phase 3

A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator’s Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy

Not yet recruitingCTIS2024-519818-31-01

Genmab A/SEndometrial Cancer Advanced, Metastatic, or Primary Unresectable Endometrial Cancer +1

Target: 51Updated: 2026-03-27

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L PlatinumBased Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

Not yet recruitingCTIS2025-522167-15-00

Genmab A/SOvarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)

Target: 157Updated: 2026-07-02

A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer

Not yet recruitingCTIS2025-524202-15-00

Genmab A/SRecurrent Platinum-Sensitive Ovarian Cancer

Target: 83Updated: 2026-09-18